Drug Trial Radar · NCT05890053
To Evaluate the Long-term Safety and Efficacy of HSK16149 in Chinese Patients With Peripheral Neuralgia
Last checked: Nov 20, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
301
Actual
Start
Feb 17, 2022
Primary completion
Jul 30, 2023
Study completion Aug 7, 2023
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigate the long-term(52 weeks) safety and efficacy of HSK16149 capsules in Chinese patients with periphcral neuralgia
Conditions
- Peripheral Neuropathic Pain
Interventions
HSK16149 40mg BIDDrug
HSK16149 40mg , orally twice a day, treatment period; 52-weeks fixed dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the long-term safety of HSK16149 capsules in Chinese patients with peripheral neuralgia.Time frame: From week 1 to week 53
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
The Second Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Peking University First Hospital
Beijing, Beijing Municipality, China
Beijing Pinggu District Hospital
Beijing, Beijing Municipality, China
Emergency General Hospital
Beijing, Beijing Municipality, China
The Three Gorges Hospital Affiliated to Chongqing Medical University
Chongqing, Chongqing Municipality, China
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
Cangzhou People's Hospital
Cangzhou, Hebei, China
The Third Hospital of Hebei Medical University
Shijiangzhuang, Hebei, China
Kaifeng Hospital of Traditional Chinese Medicine
Kaifeng, Henan, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
Nanyang First People's Hospital
Nanyang, Henan, China
Wuhan Central Hospital
Wuhan, Hubei, China
Nanjing First People's Hospital
Nanjing, Jiangsu, China
Pingxiang People's Hospital
Pingxiang, Jiangxi, China
The First Hospital of Jilin University
Changchun, Jilin, China
Baotou Central Hospital
Baotou, Neimenggu, China
Jinan Central Hospital
Jinan, Shandong, China
The First Affiliated Hospital of Xi'an Medical University
Xi’an, Shanxi, China
Yuncheng Central Hospital
Yuncheng, Shanxi, China
The Second People's Hospital of Yibin
Yibin, Sichuan, China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Taizhou First People's Hospital
Taizhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.